HomeAI · summaries
Storia in 3 fonti
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from…
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
- ·
endpoints.news
Summit reports two-year survival data for Western patients, though context lacking
Summit's ivonescimab cuts death risk 24% (HR 0.76) in Western NSCLC patients at the 2-year HARMONi mark, but median survival figures remain undisclosed.
